See relapses that others miss.
Foresight’s peer-reviewed and proprietary minimal residual disease (MRD) technology has been validated in hundreds of real-world samples from patients with B-cell malignancies, lung cancer, and breast cancer[+]. At the end of therapy Foresight detected circulating tumor DNA in all the patients who would relapse.
Existing methods missed most of them.View Publications
See levels below 1 part per million
By tracking unique genomic differences between cancer and healthy cells with unparalleled accuracy, Foresight can detect ctDNA levels below 1 part per million, which is up to 100 times lower than other methods.